{"log_id": 9040465880521718058, "direction": 0, "words_result_num": 51, "words_result": [{"probability": {"variance": 0.006424, "average": 0.982499, "min": 0.465816}, "location": {"width": 796, "top": 155, "height": 27, "left": 240}, "words": "织感染的、微生物学可评估患者的治愈率在利奈唑胺治疗组为26/33(79%),在万古霉素组"}, {"probability": {"variance": 0.000166, "average": 0.987317, "min": 0.96813}, "location": {"width": 134, "top": 186, "height": 24, "left": 242}, "words": "为24/33(73"}, {"probability": {"variance": 1e-06, "average": 0.99861, "min": 0.997014}, "location": {"width": 124, "top": 246, "height": 25, "left": 241}, "words": "糖尿病足感染"}, {"probability": {"variance": 5.8e-05, "average": 0.996426, "min": 0.95455}, "location": {"width": 745, "top": 275, "height": 27, "left": 284}, "words": "伴有临床已证实的复杂性皮肤和皮肤软组织感染(糖尿病足感染)的成年糖尿病患者"}, {"probability": {"variance": 4e-06, "average": 0.998621, "min": 0.991691}, "location": {"width": 795, "top": 306, "height": 25, "left": 241}, "words": "随机(按照2:1的比例)入选一个多中心、开放的对照临床研究,试验药物静脉或口服给"}, {"probability": {"variance": 0.000361, "average": 0.994702, "min": 0.879985}, "location": {"width": 793, "top": 336, "height": 26, "left": 242}, "words": "药,总疗程14至28天。一组患者利奈唑胺静脉或口服给药600mg每12小时一次;另一组"}, {"probability": {"variance": 0.005345, "average": 0.979015, "min": 0.499496}, "location": {"width": 796, "top": 366, "height": 26, "left": 241}, "words": "氨苄西林/舒巴坦静脉给药1.5至3g或者阿莫西林/克拉维酸口服500mg至875mg每8至12"}, {"probability": {"variance": 0.000829, "average": 0.985172, "min": 0.882132}, "location": {"width": 795, "top": 394, "height": 28, "left": 242}, "words": "小时(q8-12h)一次。在氨苄西林/舒巴坦没有上市的国家,静脉给药选用阿莫西林/克拉"}, {"probability": {"variance": 0.000585, "average": 0.991252, "min": 0.865525}, "location": {"width": 785, "top": 426, "height": 28, "left": 243}, "words": "维酸500mg至2g每6小时(q6h)给药一次。对照组的患者如果足部感染部位检出MRSA"}, {"probability": {"variance": 6e-05, "average": 0.996786, "min": 0.955715}, "location": {"width": 791, "top": 457, "height": 25, "left": 244}, "words": "可用静脉给予万古霉素1g每12小时一次。两组患者中,如果在感染部位分离出革兰阴性杆"}, {"probability": {"variance": 0.000121, "average": 0.996208, "min": 0.932258}, "location": {"width": 784, "top": 486, "height": 28, "left": 243}, "words": "菌,可以给予氨曲南1g至2g,每8至12小时一次。所有的患者可以接受适当的辅助治疗"}, {"probability": {"variance": 7.2e-05, "average": 0.997061, "min": 0.947971}, "location": {"width": 795, "top": 517, "height": 26, "left": 244}, "words": "治疗糖尿病足感染的典型措施如:清创术和减负荷术,绝大多数患者接受了此类治疗。意向"}, {"probability": {"variance": 0.000381, "average": 0.991534, "min": 0.906611}, "location": {"width": 790, "top": 547, "height": 26, "left": 244}, "words": "治疗(ITT)人群包括,241例利奈唑胺治疗和120例对照药物治疗的患者。212例(86%)"}, {"probability": {"variance": 0.000277, "average": 0.99205, "min": 0.930022}, "location": {"width": 794, "top": 576, "height": 26, "left": 243}, "words": "利奈唑胺治疗组患者和105例(85%)对照药物治疗组患者作为临床可评估患者。ITT人群"}, {"probability": {"variance": 0.004693, "average": 0.97149, "min": 0.660646}, "location": {"width": 795, "top": 605, "height": 28, "left": 243}, "words": "的治愈率,在利奈唑胺治疗组患者为68.5%(1651241),对照药物组为64%(7/120),评价时"}, {"probability": {"variance": 0.000123, "average": 0.99572, "min": 0.934523}, "location": {"width": 796, "top": 634, "height": 28, "left": 244}, "words": "将不能判定和缺失的结果归为治疗失败。临床可评估的患者中(除外结果为不能判定和缺失"}, {"probability": {"variance": 0.002326, "average": 0.988725, "min": 0.662536}, "location": {"width": 782, "top": 665, "height": 27, "left": 243}, "words": "的患者)的治愈率,在利奈唑胺治疗组为83%(159/192),在对照药物组为73%(74/101)"}, {"probability": {"variance": 0.00033, "average": 0.993043, "min": 0.894045}, "location": {"width": 772, "top": 694, "height": 29, "left": 267}, "words": "项重要的post-hoc分析,针对从感染部位或血液中分离出革兰阳性菌的患者,利奈唑胺组"}, {"probability": {"variance": 0.000203, "average": 0.995847, "min": 0.908686}, "location": {"width": 791, "top": 724, "height": 28, "left": 250}, "words": "21例,对照组60例,较总体研究人群,这些患者更少有伴发骨髓炎的证据且没有应用被"}, {"probability": {"variance": 0.001749, "average": 0.981734, "min": 0.765654}, "location": {"width": 794, "top": 754, "height": 31, "left": 246}, "words": "禁用的抗生素。根据该分析,利奈唑胺治疗的患者治愈率为71%(86/121),对照药物组为63%"}, {"probability": {"variance": 0.005604, "average": 0.986231, "min": 0.502415}, "location": {"width": 796, "top": 787, "height": 25, "left": 245}, "words": "38/60)。未根据辅助治疗对于上述分析进行调整。微生物学可评估患者不同病原菌的治愈率"}, {"probability": {"variance": 5e-06, "average": 0.998356, "min": 0.994525}, "location": {"width": 69, "top": 819, "height": 24, "left": 246}, "words": "见表14"}, {"probability": {"variance": 0.003623, "average": 0.978362, "min": 0.669501}, "location": {"width": 663, "top": 845, "height": 29, "left": 310}, "words": "表14微生物学可评估的糖尿病足感染成年患者治愈检测随访时的治愈率"}, {"probability": {"variance": 3e-06, "average": 0.998448, "min": 0.995965}, "location": {"width": 66, "top": 881, "height": 25, "left": 338}, "words": "病原体"}, {"probability": {"variance": 0, "average": 0.9998, "min": 0.999672}, "location": {"width": 83, "top": 881, "height": 23, "left": 729}, "words": "治愈"}, {"probability": {"variance": 0.000806, "average": 0.987681, "min": 0.912651}, "location": {"width": 151, "top": 915, "height": 24, "left": 561}, "words": "利奈唑胺nN(%"}, {"probability": {"variance": 0.001687, "average": 0.98308, "min": 0.874483}, "location": {"width": 213, "top": 909, "height": 33, "left": 824}, "words": "对照药物nN(%"}, {"probability": {"variance": 8.5e-05, "average": 0.994667, "min": 0.972382}, "location": {"width": 142, "top": 951, "height": 25, "left": 248}, "words": "金黄色葡萄球菌"}, {"probability": {"variance": 8.5e-05, "average": 0.993302, "min": 0.972834}, "location": {"width": 78, "top": 951, "height": 22, "left": 599}, "words": "4963(78"}, {"probability": {"variance": 0.044182, "average": 0.835221, "min": 0.454294}, "location": {"width": 249, "top": 945, "height": 34, "left": 863}, "words": "209(6"}, {"probability": {"variance": 1e-06, "average": 0.998672, "min": 0.996885}, "location": {"width": 247, "top": 981, "height": 27, "left": 245}, "words": "耐甲氧西林金黄色葡萄球菌"}, {"probability": {"variance": 0.00145, "average": 0.954561, "min": 0.871597}, "location": {"width": 68, "top": 982, "height": 20, "left": 601}, "words": "12/17(71"}, {"probability": {"variance": 0.001525, "average": 0.961393, "min": 0.907841}, "location": {"width": 47, "top": 980, "height": 23, "left": 879}, "words": "/3(6"}, {"probability": {"variance": 1e-06, "average": 0.999413, "min": 0.998045}, "location": {"width": 101, "top": 1014, "height": 25, "left": 248}, "words": "无乳链球菌"}, {"probability": {"variance": 0.002615, "average": 0.962578, "min": 0.842898}, "location": {"width": 81, "top": 1012, "height": 22, "left": 599}, "words": "25/29(86)"}, {"probability": {"variance": 0.020233, "average": 0.932496, "min": 0.58501}, "location": {"width": 70, "top": 1012, "height": 21, "left": 871}, "words": "9l6(56)"}, {"probability": {"variance": 4e-06, "average": 0.997928, "min": 0.995023}, "location": {"width": 83, "top": 1079, "height": 25, "left": 249}, "words": "儿童患者"}, {"probability": {"variance": 1.9e-05, "average": 0.996485, "min": 0.983506}, "location": {"width": 248, "top": 1107, "height": 27, "left": 247}, "words": "革兰阳性微生物所致的感染"}, {"probability": {"variance": 2.9e-05, "average": 0.996813, "min": 0.97355}, "location": {"width": 733, "top": 1134, "height": 30, "left": 309}, "words": "项临床研究提供了利奈唑胺用于治疗儿童患者革兰阳性菌所致感染,包括甲氧西林耐"}, {"probability": {"variance": 0.000123, "average": 0.996142, "min": 0.929766}, "location": {"width": 794, "top": 1164, "height": 28, "left": 249}, "words": "药和敏感的金黄色葡萄球菌和万古霉素耐药的屎肠球菌引起的院内获得性肺炎、复杂性皮肤"}, {"probability": {"variance": 5e-06, "average": 0.997791, "min": 0.989687}, "location": {"width": 790, "top": 1193, "height": 30, "left": 250}, "words": "和皮肤软组织感染、导管相关性菌血症、原因不明的菌血症和其他感染的安全性和有效性经"}, {"probability": {"variance": 1.7e-05, "average": 0.997834, "min": 0.97877}, "location": {"width": 796, "top": 1222, "height": 34, "left": 248}, "words": "验。儿童患者的年龄从刚出生至11岁,所患的感染已证实或怀疑由革兰阳性菌所致,患者"}, {"probability": {"variance": 0.000136, "average": 0.995707, "min": 0.938206}, "location": {"width": 792, "top": 1255, "height": 31, "left": 250}, "words": "被入选至一个随机、开放的、阳性药物对照的临床研究中。一组患者每8小时按10mg/kg"}, {"probability": {"variance": 0.00046, "average": 0.993453, "min": 0.859744}, "location": {"width": 796, "top": 1284, "height": 35, "left": 249}, "words": "静脉输注利奈唑胺,随后改为每8小时按10mg/kg口服利奈唑胺混悬剂。第二组患者根据"}, {"probability": {"variance": 0.000666, "average": 0.988086, "min": 0.867357}, "location": {"width": 795, "top": 1317, "height": 30, "left": 248}, "words": "年龄和肾清除率,按10-15mg/kg每6-24小时静脉输注万古霉素。证实为万古霉素耐药的肠"}, {"probability": {"variance": 3.9e-05, "average": 0.996056, "min": 0.975601}, "location": {"width": 791, "top": 1347, "height": 30, "left": 251}, "words": "球菌感染的患者入选第三组,每8小时按10mg/kg静注或口服利奈唑胺。所有的患者治疗"}, {"probability": {"variance": 0.00404, "average": 0.981832, "min": 0.599873}, "location": {"width": 788, "top": 1374, "height": 35, "left": 255}, "words": "0-28天,如有临床指征可合并应用针对革兰阴性菌感染的抗生素。在意向治疗的患者(ITT)"}, {"probability": {"variance": 0.001061, "average": 0.989566, "min": 0.798221}, "location": {"width": 793, "top": 1405, "height": 33, "left": 251}, "words": "人群中,206例患者随机入选利奈唑胺组,102例患者随机入选万古霉素组。117例(57%)"}, {"probability": {"variance": 0.000209, "average": 0.992918, "min": 0.926151}, "location": {"width": 796, "top": 1435, "height": 32, "left": 251}, "words": "利奈唑胺组的患者和55例(54%)万古霉素组的患者为临床可评估患者。意向治疗的患者"}, {"probability": {"variance": 1e-06, "average": 0.998743, "min": 0.996473}, "location": {"width": 139, "top": 1480, "height": 22, "left": 580}, "words": "第17页,共25页"}, {"probability": {"variance": 0.000326, "average": 0.984776, "min": 0.949607}, "location": {"width": 40, "top": 1507, "height": 20, "left": 341}, "words": "20130"}], "language": 3}